Skip to content

Early recognition of cardiovascular disease

Reviving Early Diagnosis of Cardiovascular Disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON24396
Enrollment
1300
Registered
2018-05-01
Start date
2018-12-01
Completion date
Unknown
Last updated
2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovasculaire ziekten Hart- en vaatziekten Atriumfibrilleren Coronairlijden Hartfalen Cardiovascular disease atrial fibrillation coronary artery disease heart failure

Interventions

Patients in the intervention arm will undergo the Early Diagnosis Strategy. The Early Diagnosis Strategy consists of a questionnaire that can be filled in online prior to their routine visit to their

Sponsors

University Medical Center Utrecht
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Currently enrolled in a primary care (chronic) disease management program for either COPD or T2D 2. Age 18 years or over 3. Willing to sign informed consent

Exclusion criteria

Exclusion criteria: 1. Not proficient in Dutch or having severe cognitive impairment (i.e. not able to understand and correctly fill in the questionnaire) 2. Having a triple diagnosis of HF, CAD and AF. Confirmed with echocardiography in case of HF, with coronary angiography, exercise-test, stress-echo, stress MRI, SPECT-CT/MIBI or calcium score > 100 on CT-scan in case of CAD, with electrocardiography in case of AF.

Design outcomes

Primary

MeasureTime frame
The number of newly detected cases with CVDs (heart failure, atrial fibrillation or coronary artery disease) in both arms, and the subsequent targeted therapies these new cases received.

Secondary

MeasureTime frame
1. the added diagnostic value of family history taking, and, in women, reproductive history 2. the added diagnostic value of biomarkers other than BNP, i.e. high-sensitive troponine (hs-Tn), growth differentiation factor 15 (GDF-15),ST-2? 3. the cost-effectiveness of the Early Diagnosis Strategy compared to usual care

Contacts

Public ContactAmy Groenewegen

Postbus 85500

a.groenewegen-7@umcutrecht.nl088 75 69 619

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)